Prostaglandin I2 analogue, iloprost, down regulates mitogen-activated protein kinases of macrophages

Journal of Surgical Research

Volumn 76, Issue 2, 1998, Pages 159-164

  Lo, Chong Jeh ^a   Fu, Minjuan ^a   Lo, F Rosa ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Iloprost; MAPK; PD98059; SB202190; TNF

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; ILOPROST; MITOGEN ACTIVATED PROTEIN KINASE; PROSTACYCLIN DERIVATIVE; LIPOPOLYSACCHARIDE; PROTEIN KINASE (CALCIUM,CALMODULIN); TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; CONFERENCE PAPER; DRUG EFFECT; DRUG HALF LIFE; ENZYME ACTIVATION; MACROPHAGE ACTIVATION; NEGATIVE FEEDBACK; NONHUMAN; PRIORITY JOURNAL; RABBIT; RECEPTOR DOWN REGULATION; REGULATORY MECHANISM; REPERFUSION INJURY; TISSUE INJURY; ANIMAL; ARTICLE; BIOSYNTHESIS; CELL LINE; ENZYMOLOGY; ESCHERICHIA COLI; LUNG ALVEOLUS MACROPHAGE; MACROPHAGE; MALE; METABOLISM; MOUSE; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CA(2+)-CALMODULIN DEPENDENT PROTEIN KINASE; CELL LINE; ENZYME ACTIVATION; ESCHERICHIA COLI; ILOPROST; LIPOPOLYSACCHARIDES; MACROPHAGES; MACROPHAGES, ALVEOLAR; MALE; MICE; RABBITS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032056346     PISSN: 00224804     EISSN: None     Source Type: Journal    
DOI: 10.1006/jsre.1998.5312     Document Type: Conference Paper

References (40)

1. Beal A. L., Cerra F. B. Multiple organ failure syndrome in the 1990s. J. Am. Med. Assoc. 271:1994;226.
2. Bone R. C. Toward an epidemiology and natural history of SIRS (systemic inflammatory response syndrome). J. Am. Med. Assoc. 268:1992;3452.
3. Nathan C. F. Secretory products of macrophages. J. Clin. Invest. 79:1987;319.
4. Johnston R. B. Monocytes and macrophages. N. Engl. J. Med. 318:1988;747.
5. Malech H. L., Gallin J. I. Neutrophils in human diseases. N. Engl. J. Med. 317:1987;687.
6. Pober J. S., Cotran R. S. Cytokines and endothelial cell biology. Physiol. Rev. 70:1990;427.
7. Collins T. Adhesion molecules in leukocyte emigration. Sci. Med. 2:1995;28.
8. Pohlman T. H., Stannes K. A., Beatty P. G., Ochs H. D., Harlan J. M. An endothelial cell surface factor(s) induced in vitro by lipopolysaccharide, interleukin 1, and tumor necrosis factor-α increases neutrophil adherence by a CDw18-dependent mechanism. J. Immunol. 12:1986;4548.
9. Bevilacqua M. P. Endothelial-leukocyte adhesion molecules. Annu. Rev. Immunol. 11:1993;767.
10. Bevilacqua M. P., Pober J. S., Majeau G. R., Fiers W., Cotran R. S., Gimbrone M. A. Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: Characterization and comparison with the actions of interleukin 1. Proc. Natl. Acad. Sci. USA. 83:1986;4533.
11. Levi M., ten Cate H., van der Poll T., van Deventer S. J. M. Pathogenesis of disseminated intravascular coagulation in sepsis. J. Am. Med. Assoc. 270:1993;975.
12. Williams J. G., Garcia I. A., Maier R. V. Endothelial regulation of macrophage tumor necrosis factor production. Surg. Forum. 43:1991;94.
13. Lo C-J., Garcia I., Maier R. V. Tumor necrosis factor production by endotoxin-stimulated macrophages is regulated by endothelium. Shock. 3:1995;37.
14. Moncada S., Gryglewski R., Bunting S., Vane J. R. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature. 263:1976;663.
15. Skuballa W., Vorbruggen H. A new route to 6a-carbacyclins-synthesis of a stable biologically potent prostacyclin analogue. Angew. Chem. Int. Ed. Engl. 20:1981;1046.
16. Moncada S., Vane J. R. Prostacyclin and its clinical applications. Ann. Clin. Res. 16:1984;241.
17. Krause W., Krais T. Pharmacokinetics and pharmacodynamics of the prostacyclin analogue iloprost in man. Eur. J. Clin. Pharmacol. 30:1986;61.
18. Riva C. M., Morganroth M. L., Ljungman A. G., Shoeneich S. O., Marks R. M., Todd R. F., Ward P. A., Boxer L. A. Iloprost inhibits neutrophil-induced lung injury and neutrophil adherence to endothelial monolayers. Am. J. Resp. Cell Mol. Biol. 3:1990;301.
19. Crutchley D. J., Solomon D. E., Conanan L. B. Prostacyclin analogues inhibit tissue factor expression in the human monocytic cell line THP-1 via a cyclic-AMP-dependent mechanism. Art. Thromb. 12:1992;664.
20. Crutchley D. J., Conanan L. B., Toledo A. W., Solomon D. E., Que B. G. Effects of prostacyclin analogues on human endothelial cell tissue factor expression. Art. Thromb. 13:1993;1082.
21. Rasmussen I., Arvidsson D., Zak A., Haglund U. Splanchnic and total body oxygen consumption in experimental fecal peritonitis in pigs: Effects of dextran and iloprost. Cir. Shock. 36:1992;299.
22. Grundmann H., Hahnle U., Hegenscheid B., Sahlmuller G., Bienzle U., Blitstein-Willinger E. Inhibition of endotoxin-induced macrophage tumor necrosis factor expression by a prostacyclin analogue and its beneficial effect in experimental lipopolysaccharide intoxication. J. Infect. Dis. 165:1992;501.
23. Cano E., Mahadevan L. C. Parallel signal processing among mammalian MAPKs. Trends Biochem. Sci. 20:1995;117.
24. Ruderman J. V. MAP kinase and the activation of quiescent cells. Curr. Opin. Cell Biol. 5:1993;207.
25. Weinstein S. L., Sanghera J. S., Lemke K., DeFranco A. L., Pelech S. L. Bacterial lipopolysaccharide induces tyrosine phosphorylation and activation of mitogen-activated protein kinases in macrophages. J. Biol. Chem. 267:1992;14955.
26. Han J., Lee J.-D., Tobias P. S., Ulevitch R. J. Endotoxin induces rapid protein tyrosine phosphorylation in 70Z/3 cells expressing CD14. J. Biol. Chem. 268:1993;25009.
27. Lo C-J., Fu M., Kim B. Macrophage TNF mRNA expression is modulated by protease inhibitors. J. Surg. Res. 69:1997;408.
28. Parrillo J. E. Management of septic shock: Present and future. Ann. Intern. Med. 115:1991;491.
29. Carrico C. J., Meakins J. L., Marshall J. C., Fry D., Maier R. V. Multiple-organ-failure syndrome. Arch. Surg. 121:1985;196.
30. Border J. R. Hypothesis: Sepsis, multiple systems organ failure, and the macrophage. Arch. Surg. 123:1988;285.
31. Beutler B., Krochin N., Milsark I. W., Luedke C., Cerami A. Control of cachectin (tumor necrosis factor) synthesis: Mechanisms of endotoxin resistance. Science. 232:1986;977.
32. Beutler B., Cerami A. The biology of cachectin/TNF-α primary mediator of the host response. Ann. Rev. Immunol. 7:1989;625.
33. Michie H. R., Spriggs D. R., Manogue K. R., Sherman M. L., Revhaug A., O'Dwyer S. T., Arthur K., Dinarello C. A., Cerami A., Wolff S. M., Kufe D. W., Willmore D. W. Tumor necrosis factor and endotoxin induce similar metabolic responses in human beings. Surgery. 104:1988;280.
34. Tracey K. J., Beutler B., Lowry S. F., Merryweather J., Wolpe S., Milsark I. W., Hariri R. J., Fahey T. J., Zentella A., Albert J. D., Shires G. T., Cerami A. Shock and tissue injury induced by recombinant human cachectin. Science. 234:1986;470.
35. Pober J. S., Cotran R. S. Cytokines and endothelial cell biology. Physiol. Rev. 70:1990;427.
36. Gamble J. R., Harlan J. M., Klebanoff S. J., Vadas M. A. Stimulation of the adherence of neutrophils to umbilical vein endothelium by human recombinant tumor necrosis factor. Proc. Natl. Acad. Sci. USA. 82:1985;8667.
37. Kawakami M., Ishibashi S., Ogawa H., Murase T., Takaku F., Shibata S. Cachectin/TNF as well as interleukin-1 induces prostacyclin synthesis in cultured vascular endothelial cells. Biochem. Biophys. Res. Commun. 141:1986;482.
38. Marshall C. J. Specificity of receptor tyrosine kinase signaling: Transient versus sustained extracellular signal-regulated kinase activation. Cell. 80:1995;179.
39. Kyriakis J. M., Banerjee P., Nikolakaki E., Dai T., Rubie E. A., Ahmad M. F., Avruch J., Woodgett J. R. The stress-activated protein kinase subfamily of c-jun kinases. Nature. 369:1994;156.
40. Han J., Lee J-D., Bibbs L., Ulevitch R. J. A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. Science. 265:1994;808.